Robert W. Baird Cuts SFBC to Neutral from Outperform

Cites increasing lack of confidence in the company following a Bloomberg report that SFBC allowed an infected patient into a trial

Robert W. Baird cut its rating on SFBC International(SFCC ) to neutral from outperform, explaining that "material risks have emerged" at the drug development company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.